Merus NV
NASDAQ:MRUS

Watchlist Manager
Merus NV Logo
Merus NV
NASDAQ:MRUS
Watchlist
Price: 90 USD -7.14% Market Closed
Market Cap: $6.8B

Net Margin

-673.1%
Current
Declining
by 186%
vs 3-y average of -487%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-673.1%
=
Net Income
$-381m
/
Revenue
$56.6m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-673.1%
=
Net Income
$-381m
/
Revenue
$56.6m

Peer Comparison

Country Company Market Cap Net
Margin
NL
Merus NV
NASDAQ:MRUS
6.8B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
395.2B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.2B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175.6B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.4B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.9B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.8B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.3B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 96% of companies in Netherlands
Percentile
4th
Based on 629 companies
4th percentile
-673.1%
Low
-21 487.9% — 0.2%
Typical Range
0.2% — 14.2%
High
14.2% — 87 885%
Distribution Statistics
Netherlands
Min -21 487.9%
30th Percentile 0.2%
Median 5.3%
70th Percentile 14.2%
Max 87 885%

Merus NV
Glance View

Merus NV, a Dutch biotechnology company, stands at the forefront of innovative cancer therapies, channeling its efforts into research and development of multispecific antibodies. Its proprietary technology platform, Biclonics®, ingeniously harnesses the power of full-length human antibodies to target multiple pathways in the treatment of cancer. Each Biclonics® candidate is designed to bind simultaneously to more than one target, acting like a precision-guided missile that seeks out cancer cells and disrupts the signaling processes that allow tumors to grow and spread. This cutting-edge approach aims to overcome the limitations of traditional monoclonal antibodies and offers promising new avenues for tackling cancer’s incessant complexity. The company's business model is built upon a robust pipeline strategy, where promising drug candidates are both developed in-house and guided through strategic collaborations with larger pharmaceutical entities. These collaborations often involve licensing agreements that provide Merus NV with milestone payments and royalties, creating a significant revenue stream. As these partnerships amplify its reach and bolster its financial health, Merus maintains a primary focus on advancing its leading drug candidates through clinical trials. By aligning groundbreaking science with strategic collaborations, Merus NV works to convert its innovations into viable products that can potentially transform the landscape of cancer treatment, striving to turn scientific potential into practical solutions and profitable outcomes.

MRUS Intrinsic Value
28.01 USD
Overvaluation 69%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-673.1%
=
Net Income
$-381m
/
Revenue
$56.6m
What is Merus NV's current Net Margin?

The current Net Margin for Merus NV is -673.1%, which is below its 3-year median of -487%.

How has Net Margin changed over time?

Over the last 3 years, Merus NV’s Net Margin has decreased from -139.5% to -673.1%. During this period, it reached a low of -684.7% on Jun 30, 2025 and a high of -139.5% on Sep 30, 2022.

Back to Top